Pitule et al. firstly found that SLC26A2 expression was significantly down-regulated in colorectal cancer (CRC) tissues, and patients with a higher expression of SLC26A2 in tumor tissues had a longer overall survival (OS) and disease-free interval (DFI) [13]. Here, SLC26A2 is linked to colorectal carcinoma.